lopinavir has been researched along with atazanavir sulfate in 184 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 76 (41.30) | 29.6817 |
| 2010's | 95 (51.63) | 24.3611 |
| 2020's | 13 (7.07) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, JG | 1 |
| Korn, K; Moschik, G; Paatz, C; Schmidt, B; Schnell, T; Thein, C; Walter, H | 1 |
| Moyle, GJ | 1 |
| Sax, PE | 1 |
| Wehr, A | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Currie, A; Fiedorek, FT; Grasela, DM; Haas, DW; Hodder, SL; Noor, MA; O'Mara, E; Parker, RA | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 2 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Adler, E; Cohen, C; Fessel, WJ; Gladysz, A; Gonzalez-Garcia, J; McGovern, R; McLaren, C; Nieto-Cisneros, L; Zala, C | 1 |
| Hill, A | 1 |
| Hruz, PW; Yan, Q | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Decosterd, LA; Franc, C; Guignard, N; Khonkarly, M; Rochat, B; Tarr, PE; Telenti, A | 1 |
| Crane, HM; Kitahata, MM; Van Rompaey, SE | 1 |
| Azuaje, C; Crespo, M; Curran, A; Diaz, M; Feijoo, M; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E | 1 |
| Flint, OP; Maa, JF; Noor, MA; Parker, RA | 1 |
| Johnson, M | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Aouadi, M; Binétruy, B; Cardot-Leccia, N; Dellamonica, P; Durant, J; Garraffo, R; Heripret, L; Lavrut, T; Le Marchand-Brustel, Y; Perrin, C; Prot, M | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Chan-Tack, KM; Fantry, LE; Gilliam, BL; Qaqish, RB; Redfield, RR; Rode, RA | 1 |
| Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| DiFrancesco, R; Fischl, MA; Gripshover, B; Hochreitter, J; Keil, K; Morse, GD; Reichman, RC; Zingman, BS | 1 |
| Brazeau, D; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Ma, Q; Morse, GD; Reichman, RC; Slish, JC; Venuto, CS; Zingman, BS | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V | 1 |
| Agarwala, S; Barditch-Crovo, P; Carson, K; Flexner, C; Fuchs, E; Parsons, T; Pham, PA; Vasist, L | 1 |
| Clavel, F; Dam, E; Essioux, L; Faudon, JL; Hill, A; Lebel-Binay, S; Rochas, S; Schutz, M; Thibaut, L; Thomas, CM | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Back, D; Boffito, M; Bonora, S; D'Avolio, A; Else, L; Gazzard, B; Mandalia, S; Moyle, G; Nelson, M; Pozniak, A; Waters, LJ | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Boston, NS; Brazeau, D; Catanzaro, L; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, B; Ma, Q; Morse, GD; Reichman, RC; Slish, J; Zingman, BS | 1 |
| Arribas, JR; Pulido, F | 1 |
| Barreiro, P; Blanco, F; de Mendoza, C; García-Gasco, P; González-Lahoz, J; Martín-Carbonero, L; Morello, J; Rivas, P; Rodríguez-Novoa, S; Ruiz-Sancho, A; Soriano, V; Vispo, E | 1 |
| Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN | 1 |
| Castagna, A; Caumo, A; Galli, L; Guffanti, M; Lazzarin, A; Luzi, L; Perseghin, G | 1 |
| Hruz, PW; Jay, PY; Struthers, H; Yan, Q | 1 |
| Bacarelli, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Navarra, P; Ragazzoni, E; Regazzi, M; Villani, P | 1 |
| Babacan, E; Kaykhin, P; Lötsch, J; Staszewski, S; Stephan, C; Stürmer, M; von Hentig, N | 1 |
| Beck, K; Cai, Y; Causemaker, SJ; Chiu, YL; Doan, T; Esslinger, HU; Hanna, GJ; King, KR; Klein, CE; Podsadecki, TJ | 1 |
| Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
| Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A | 1 |
| Dubé, MP; Greenwald, M; Mather, KJ; Shen, C | 1 |
| Fu, W; Hu, WS; Moore, MD; Nagashima, K; Pathak, VK; Ptak, RG; Soheilian, F | 1 |
| Keiser, PH; Nassar, N | 1 |
| Frank, I; Torti, C | 1 |
| Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Thiry, A; Yang, R | 1 |
| Chin, BS; Choi, H; Choi, JY; Choi, SH; Han, SH; Jeong, SJ; Kim, CO; Kim, JM; Kim, MS; Lee, HS; Song, YG | 1 |
| Batterham, M; Chan, DJ; McNally, L; Ray, JE; Smith, DE | 1 |
| Louis, JM; Sayer, JM | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Khoo, S; Moyle, G; Pozniak, A; Sousa, M; Taylor, J | 1 |
| Bierman, WF; Boucher, CA; Danner, SA; Nijhuis, M; van Agtmael, MA | 1 |
| Ameli, N; Anastos, K; Bacchetti, P; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Hyman, CL; Levine, A; Young, M | 1 |
| Dietz, B; Rajagopalan, R; Simpson, KN | 1 |
| Moreno, V; Valencia, ME | 1 |
| Aranda, M; Arranz, JA; Blanco, JL; Clotet, B; Cosin, J; Cruceta, A; Dalmau, D; Domingo, P; Ferrer, E; García, I; Gatell, JM; Gutiérrez, F; Knobel, H; Lazzari, Ed; Llibre, JM; Mallolas, J; Martínez, E; Milinkovic, A; Murillas, J; Pedrol, E; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Vidal, F | 1 |
| Chen, CY; Grinspoon, SK; Hadigan, CM; Joy, T; Liebau, JG; Makimura, H; Robbins, GK; Stanley, TL; Thomas, BJ; Weise, SB | 1 |
| Chetchotisakd, P | 1 |
| Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| Sankawa, Y | 1 |
| Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Sabin, C; Stöhr, W; Winston, A | 1 |
| Anceschi, MM; Ascenzi, P; Ivanovic, J; Mattia, E; Narciso, P; Nicastri, E; Notari, S; Pisani, G; Pucillo, LP; Signore, F; Tempestilli, M; Vallone, C | 1 |
| Andersson, MC; Böttiger, Y; Flamholc, L; Gisslén, M; Hagberg, L; Josephson, F; Ormaasen, V; Sönnerborg, A; Vesterbacka, J | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Carper, MJ; Lei, X; Ramanadham, S; Richmond, SR; Yarasheski, KE; Zhang, S | 1 |
| Hylemon, PB; Li, X; Liang, G; Pandak, WM; Studer, EJ; Wang, G; Xiao, J; Zha, W; Zhou, H | 1 |
| Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N | 1 |
| Burger, DM; Faraj, D; Gelinck, L; Kroon, F; Kuks, PF; Richter, C; Van der Ende, ME; Van der Ven, A; van Luin, M; Van Schaik, RH; Visser, M; Wit, FW | 1 |
| Lisovsky, I; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA | 1 |
| Andersson, LM; Andersson, O; Edén, A; Flamholc, L; Gisslén, M; Josephson, F; Nilsson, S; Ormaasen, V; Säll, C; Sönnerborg, A; Svedhem, V; Tunbäck, P | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Auclair, M; Bastard, JP; Boccara, F; Capeau, J; Caron-Debarle, M; Cohen, A; Lefèvre, C; Prot, M | 1 |
| Bierman, WF; Danner, SA; Jansen, G; Scheffer, GL; Scheper, RJ; Schoonderwoerd, A; van Agtmael, MA | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| Antoine, B; Capeau, J; Chapron, C; Kadiri, S; Leroyer, S; Quette, J; Vatier, C | 1 |
| Absalon, J; Johnson, M; McGrath, D; Sheppard, L; Squires, KE; Uy, J; Yang, R | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Curto, J; del Rio, L; Domingo, P; Ferrer, E; Gatell, JM; Martínez, E; Negredo, E; Ordóñez, J; Podzamczer, D; Ribera, E; Rosales, J; Saumoy, M | 1 |
| Alaeus, A; Heeg, B; Lescrauwaet, B; Neubauer, A; Sennfält, K; Thuresson, PO | 1 |
| Callebaut, C; Cihlar, T; Hruz, PW; Koster, J; Tsai, L; Xu, L; Yan, Q | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Andrews, S; Carlson, GA; Hanamsagar, R; Huang, Y; Ikezu, T; Kiyota, T; Lan, X; Peng, H; Swindells, S; Zheng, JC | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR | 1 |
| Alvarez Del Vayo Benito, C; Falcon-Neyra, L; León Leal, JA; Lopez-Cortes, LF; Neth, O; Obando, I; Ruiz-Valderas, R | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Ashton, M; Ekvall, H; Flamholc, L; Gisslén, M; Ormaasen, V; Röshammar, D; Simonsson, US; Vesterbacka, J; Wallmark, E | 1 |
| Andrade-Villanueva, J; Cheng, AK; Chuck, SL; Clotet, B; Clumeck, N; Lamarca, A; Liu, YP; Margot, N; Molina, JM; Zhong, L | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Arnaiz, JA; Clotet, B; Cruceta, A; Dalmau, D; Diaz-Brito, V; Domingo, P; García, F; Gatell, JM; Knobel, H; León, A; Peraire, J | 1 |
| Asahchop, EL; Brenner, BG; Doualla-Bell, F; Grossman, Z; Lisovsky, I; Martinez-Cajas, JL; Mendelson, E; Moisi, D; Oliveira, M; Wainberg, MA | 1 |
| Chiarella, J; DeGrosky, M; Kozal, M; Lataillade, M; Moreno, E; Seekins, D; Simen, B; St John, E; Uy, J; Yang, R | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Butcher, D; Farajallah, A; Hu, W; Juethner, S; McDonald, C; McGrath, D; Moyle, G; Uy, J; Wirtz, V | 1 |
| Baran, RW; Beck, EJ; Collomb, D; Dietz, B; Simpson, KN; Van de Steen, O | 1 |
| Arnáez, P; Esteban, M; García-Arriaza, J; Gómez, CE; Jiménez, JL; Muñoz-Fernández, MÁ | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Cavassini, M; Cusini, A; Decosterd, LA; Fux, CA; Gaudenz, R; Günthard, HF; Gutmann, C; Hirschel, B; Klimkait, T; Ledergerber, B; Opravil, M; Rohrbach, J; Vernazza, PL; Widmer, N; Yerly, S; Zenger, F | 1 |
| Butterton, JR; Feng, HP; Hughes, EA; Hulskotte, EG; O'Mara, E; Treitel, MA; van Zutven, MG; Wagner, JA; Xuan, F; Youngberg, SP | 1 |
| Aragones, AM; Cano, SM; Castello, A; Gomez-Arbones, X; Porcel, JM; Puig, T; Schoenenberger, JA | 1 |
| Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN | 1 |
| Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX | 1 |
| Bonfanti, P; Bonizzoni, E; Croce, D; Foglia, E; Porazzi, E; Restelli, U; Ricci, E; Rizzardini, G; Scolari, F | 1 |
| Anderson, PL; Erlandson, KM; Schoen, JC | 1 |
| Beaupere, C; Capeau, J; Hernandez-Vallejo, SJ; Lagathu, C; Larghero, J | 1 |
| Antinori, A; Castagna, A; d'Arminio Monforte, A; Galli, L; Gianotti, N; Lazzarin, A; Maserati, R; Quiros-Roldan, E; Salpietro, S; Torti, C | 1 |
| Bailey, JR; Chioma, S; Durand, CM; Laird, GM; Laskey, S; Moore, RD; Rabi, SA; Shan, L; Siliciano, RF | 1 |
| Amano, M; Das, D; Ghosh, AK; Mitsuya, H; Mizuno, A; Salcedo Gómez, PM; Yashchuk, S | 1 |
| Degli Antoni, A; Fiscon, M; Floridia, M; Francisci, D; Giacomet, V; Liuzzi, G; Marconi, AM; Martinelli, P; Masuelli, G; Pinnetti, C; Ravizza, M; Spinillo, A; Tamburrini, E | 1 |
| Afonso, P; Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Autran, B; Caby, F; Carcelain, G; Costagliola, D; Fourati, S; Guiguet, M; Guihot, A; Hattab, S; Katlama, C; Marcelin, AG | 1 |
| Fletcher, CV; Podany, AT; Robbins, BL; Winchester, LC | 1 |
| Farajallah, A; Hardy, H; Kaplita, S; McGrath, SJ; Moyle, GJ; Ward, D | 1 |
| Bamford, A; Foster, C; James, M; Walters, S; Xiang, N | 1 |
| Baldelli, S; Castoldi, S; Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Fucile, S | 1 |
| Alves, ÉAR; Borges, TK; de Miranda, MG; Magalhães, KG; Muniz-Junqueira, MI | 1 |
| Abgrall, S; Cain, LE; Casabona, J; Costagliola, D; Dabis, F; Esteve, A; Fehr, J; Hernán, MA; Jose, S; Justice, A; Logan, R; Meyer, L; Monge, S; Moreno, S; Muga, R; Olson, A; Paparizos, V; Pérez-Hoyos, S; Phillips, A; Reiss, P; Robins, JM; Sabin, C; Seng, R; Sterne, JA; Tate, J; Touloumi, G; van Sighem, A; Vandenhende, MA; Young, J | 1 |
| Azwa, I; Boettiger, DC; Bui, HV; Durier, N; Heng Sim, BL; Law, M; Nguyen, VK; Ruxrungtham, K | 1 |
| Adeyemo, T; Akanmu, AS; Awolola, A; Bello, FO; Kanki, PJ; Lesi, F; Ogunsola, FT; Okonkwo, P; Okwuegbuna, K; Oloko, K | 1 |
| Ascoli-Bartoli, T; Bellelli, V; Bianchi, L; Ceccarelli, G; d'Ettorre, G; De Girolamo, G; Giustini, N; Mastroianni, CM; Serafino, S; Vullo, V; Zaccarelli, M | 1 |
| Anderson, J; Barbour, A; Conway, K; Dermont, S; deRuiter, A; Dwyer, E; Flanagan, S; Hawkins, D; Hay, P; McKendry, A; Mulka, L; Perry, ME; Rodgers, M; Roedling, S; Sabin, CA; Sarner, L; Shah, R; Stevenson, J; Taylor, GP; Williams, E; Wood, C | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Ande, A; Kumar, A; Kumar, S; Li, J; Li, W; Nookala, AR; Vaidya, NK; Wang, L | 1 |
| Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP | 1 |
| Durante, W; Durante, ZE; Liu, XM; Peyton, KJ | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Alhalaweh, A; Bergström, CAS; Taylor, LS | 1 |
| Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Post, FA | 1 |
| Claiborne, DT; Collier, DA; Deymier, MJ; Goldstein, RA; Gupta, RK; Hunter, E; Prince, JL; Sutherland, KA | 1 |
| Kaleebu, P; Kapaata, AA; Kasamba, I; Kazooba, P; Lutaakome, J; Lyagoba, F; Mayanja, BN; Munderi, P; Namakoola, I | 1 |
| Chadwick, D; Hamzah, L; Jones, R; Jose, S; Nelson, M; Phillips, A; Post, FA; Sabin, CA; Trevelion, R; Williams, DI | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Abgrall, S; Arribas, JR; Barger, D; Barrufet, P; Braun, D; Caniglia, EC; Cardoso, SW; Chrysos, G; Costagliola, D; Gill, J; Gogos, C; Hauser, C; Hernán, MA; Hoyos, SP; Justice, A; Leyes, M; Lodi, S; Logan, R; Meyer, L; Moreno, S; Muga, R; Pacheco, A; Phillips, A; Porter, K; Reiss, P; Sabin, CA; Seng, R; Tate, J; van Sighem, A; Vandenhende, MA; Winston, A | 1 |
| Alvarenga, DLR; Alves, ÉAR; Calzavara-Silva, CE; de Oliveira, JG; Fiuza, JA; Gaze, ST; Oliveira, RC; Pascoal-Xavier, MA; Silva, AHDS | 1 |
| Bandera, A; Clerici, M; Fenizia, C; Giannattasio, C; Gori, A; Maloberti, A; Masetti, M; Muscatello, A; Sabbatini, F; Soria, A; Squillace, N; Trabattoni, D | 1 |
| Coetsee, M; Cohen, K; Dunn, L; Hislop, M; Kengne, AP; Leisegang, R; Maartens, G; Maharaj, S; Meintjes, G; Stewart, A; van Zyl, G | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| El-Hage, N; Karuppan, MKM; Kashanchi, F; Lapierre, J; Ojha, CR; Pawitwar, S; Rodriguez, M | 1 |
| Castelnuovo, B; Kaimal, A; Kiragga, A; Laker, EAO; Lamorde, M; Musubire, A; Nabaggala, MS; Nalwanga, D; Ratanshi, RP | 1 |
| Adenuga, BA; Rennie, TW | 1 |
| Bachovchin, W; Baldwin, MR; Chishti, AH; Hanada, T; Hegde, S; Levin, AE; Okure, C; Schiemer, J; Schwake, C; Vannier, E | 1 |
| Cecka, F; Cerveny, L; Huliciak, M; Martinec, O; Staud, F; Vokral, I | 1 |
| Abbasian, L; Davoudi-Monfared, E; Hajiabdolbaghi, M; Kazemzadeh, H; Khalili, H; Rahmani, H; Salehi, M; Yekaninejad, MS | 1 |
| Demirkan, K; Fırat, O; Yalçın, N | 1 |
| Alves, CR; Bozza, FA; Bozza, PT; Cardoso Soares, V; Carels, N; da Silva Gomes Dias, S; de Freitas, CS; Ferreira, AC; Fintelman-Rodrigues, N; Matos, AR; Mattos, M; Miranda, MD; Ribeiro Lima, C; Sacramento, CQ; Siqueira, MM; Souza da Silva, F; Souza, TML; Temerozo, JR | 1 |
| Agide, FD; Mohraz, M; Nikfar, S; Tigabu, BM | 1 |
| Dallocchio, RN; De Vito, A; Delogu, G; Dessì, A; Madeddu, G; Serra, PA | 1 |
| Alimohamadi, Y; Fard, SR; Kalantari, S; Maleki, D; Minaeian, S; Taher, MT; Yassin, Z | 1 |
| Budiman, F; Ivan, I; Juliawati, DJ; Ridjab, DA | 1 |
| Li, HY; Liu, WT; Sun, HB; Wang, W; Wu, SL; Yu, YX; Zhang, LL | 1 |
| Eugênio, E; Livinalli, A; Moraes, EL; Negrete, CL; Paes, RD; Serpa Osorio-de-Castro, CG; Sobreira da Silva, MJ | 1 |
| Abdi, A; Bavand, A; Farahani, E; Mazaherpour, H; Mazaherpour, S; Ramezani, A; Sofian, M | 1 |
| Elhadad, H; Hien, NM; Huy, NT; Tam, DNH; Tran, L | 1 |
| Atkinson, H; Coghlan, H; Edgerton, J; Elsby, R; Hodgson, D; Outteridge, S | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
11 review(s) available for lopinavir and atazanavir sulfate
| Article | Year |
|---|---|
Boosted PIs: competition hots up.
Topics: Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; Humans; Indinavir; Lopinavir; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Saquinavir | 2003 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lamivudine; Liver; Lopinavir; Middle Aged; Oligopeptides; Pyridines; Young Adult | 2013 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
Topics: Adult; Atazanavir Sulfate; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Electrocardiography; Humans; Long QT Syndrome; Lopinavir; Ritonavir; Saquinavir | 2021 |
46 trial(s) available for lopinavir and atazanavir sulfate
| Article | Year |
|---|---|
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2003 |
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Topics: Adult; Analysis of Variance; Atazanavir Sulfate; Cross-Over Studies; Double-Blind Method; Energy Metabolism; Fatty Acids, Nonesterified; Glycogen; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lipids; Lipodystrophy; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones | 2004 |
Boosted Reyataz comparable to Kaletra.
Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Oligopeptides; Probability; Pyridines; Pyrimidinones; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Cholesterol, LDL; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides | 2005 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Topics: Adult; Atazanavir Sulfate; Blood Proteins; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome | 2006 |
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Topics: Adipocytes; Adult; Atazanavir Sulfate; Cell Differentiation; Cross-Over Studies; Drug Combinations; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2007 |
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2007 |
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Pyrimidinones; RNA, Viral; Treatment Outcome | 2008 |
CASTLE study showed similar efficacy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2008 |
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Topics: Adult; Anti-HIV Agents; Anti-Ulcer Agents; Area Under Curve; Atazanavir Sulfate; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H2 Antagonists; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Pyrimidinones; Ranitidine; Ritonavir | 2008 |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2008 |
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Endothelium, Vascular; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lopinavir; Male; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome; Vasodilation | 2008 |
Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Viral Load | 2008 |
A king in the CASTLE? Optimum initial HIV protease inhibitor.
Topics: Atazanavir Sulfate; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Tablets; Viral Load | 2008 |
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2008 |
CASTLE data show no gender differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Sex Factors; Viral Load | 2008 |
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome | 2008 |
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Atazanavir Sulfate; Drug Resistance, Viral; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lipids; Liver; Lopinavir; Male; Middle Aged; Mutation; Oligopeptides; Pyridines; Pyrimidinones; Safety | 2009 |
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lopinavir; Male; Middle Aged; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2009 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome | 2010 |
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Sex Factors | 2011 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Limit of Detection; Lopinavir; Male; Middle Aged; Nonlinear Dynamics; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2011 |
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Atazanavir Sulfate; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Oligopeptides; Post-Exposure Prophylaxis; Pyridines; Ritonavir; Zidovudine | 2012 |
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Male; Medication Adherence; Oligopeptides; Pyridines; Quality of Life; Ritonavir; Surveys and Questionnaires | 2012 |
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepacivirus; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2013 |
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load | 2012 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Topics: Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxychloroquine; Intensive Care Units; Interferon beta-1a; Length of Stay; Lopinavir; Male; Middle Aged; Neoplasms; Pandemics; Patient Safety; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome | 2021 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
127 other study(ies) available for lopinavir and atazanavir sulfate
| Article | Year |
|---|---|
Report on new drugs.
Topics: Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Dioxolanes; Drugs, Investigational; Humans; Imidazoles; Lopinavir; Oligopeptides; Purine Nucleosides; Pyridines; Pyrimidinones; Pyrones; Sulfonamides; Sulfur Compounds | 2000 |
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Sulfonamides | 2003 |
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2003 |
[New treatment options for HIV-infected patients].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2004 |
[Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].
Topics: Adult; Atazanavir Sulfate; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2004 |
[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
Topics: Atazanavir Sulfate; Blood Glucose; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2004 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2005 |
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Carbamates; Deoxyglucose; Dose-Response Relationship, Drug; Furans; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Infusions, Intravenous; Insulin Resistance; Lopinavir; Male; Models, Animal; Muscle, Skeletal; Myocardium; Oligopeptides; Pyridines; Pyrimidinones; Rats; Ritonavir; Sulfonamides | 2005 |
[New data on atazanavir/r]].
Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome; Viral Load | 2005 |
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Hypertension; Indinavir; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nelfinavir; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir | 2006 |
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Combinations; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Failure; Treatment Outcome; Viral Load | 2006 |
Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Patient Selection; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
Topics: Adipose Tissue; Animals; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Hypertriglyceridemia; Lopinavir; Male; Mice; Mice, Inbred C57BL; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Messenger; Time Factors; Triglycerides | 2006 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir | 2006 |
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors | 2007 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
Topics: Atazanavir Sulfate; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Time Factors | 2007 |
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2007 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index | 2007 |
Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Topics: Atazanavir Sulfate; Cell Line, Tumor; Drug Resistance, Viral; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Oligopeptides; Pyridines; Pyrimidinones; Recombination, Genetic; Saquinavir; Transfection | 2007 |
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Substance-Related Disorders; United States | 2007 |
Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir | 2007 |
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom | 2007 |
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2007 |
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.
Topics: Animals; Atazanavir Sulfate; Blood Glucose; Cardiomyopathy, Dilated; Deoxyglucose; Disease Models, Animal; Echocardiography; Glucose Tolerance Test; Glucose Transporter Type 4; Heart Failure; HIV Protease Inhibitors; Humans; Insulin Resistance; Lopinavir; Mice; Myocardium; Oligopeptides; Pulmonary Edema; Pyridines; Pyrimidinones | 2008 |
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pilot Projects; Prospective Studies; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
Topics: Atazanavir Sulfate; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation.
Topics: Atazanavir Sulfate; Dimerization; gag Gene Products, Human Immunodeficiency Virus; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microscopy, Electron, Transmission; Oligopeptides; Pyridines; Pyrimidinones; RNA, Viral; Virion | 2008 |
Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medical Audit; Multivariate Analysis; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2008 |
Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Studies; Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Plasma; Pyridines; Pyrimidinones; RNA, Viral; Semen; Statistics as Topic; Viral Load | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Protease inhibitor levels in hair strongly predict virologic response to treatment.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Monitoring; Epidemiologic Methods; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Pyrimidinones; Ritonavir; Specimen Handling; Treatment Outcome; Viral Load | 2009 |
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Jaundice; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Torsades de Pointes; Viral Load | 2009 |
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Topics: Adult; Atazanavir Sulfate; DNA Mutational Analysis; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Young Adult | 2009 |
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Lopinavir; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2009 |
Factors influencing lopinavir and atazanavir plasma concentration.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Weight; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrimidinones; Rifabutin; United Kingdom | 2010 |
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birth Weight; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Oligopeptides; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Pyrimidinones | 2009 |
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Bilirubin; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.
Topics: Animals; Atazanavir Sulfate; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Darunavir; Dose-Response Relationship, Drug; Fatty Acid Transport Proteins; Fatty Acids; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligopeptides; Oxidation-Reduction; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides | 2010 |
Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.
Topics: Animals; Antigens, Surface; Atazanavir Sulfate; Berberine; Blotting, Western; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; ELAV Proteins; ELAV-Like Protein 1; Endoplasmic Reticulum; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; HIV Protease Inhibitors; Inflammation Mediators; Interleukin-6; Lopinavir; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA-Binding Proteins; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Topics: Adolescent; Adult; Aged; Alkynes; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proguanil; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2010 |
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Cells, Cultured; Codon; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2010 |
HIV protease inhibitors activate the adipocyte renin angiotensin system.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atazanavir Sulfate; Benzimidazoles; Benzoates; Biphenyl Compounds; HIV Protease Inhibitors; Humans; Irbesartan; Lopinavir; Mice; Oligopeptides; PPAR gamma; Pyridines; Pyrimidinones; Renin-Angiotensin System; Ritonavir; Telmisartan; Tetrazoles | 2010 |
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.
Topics: Atazanavir Sulfate; ATP-Binding Cassette Transporters; Cell Line; Drug Resistance, Multiple; Enzyme Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.
Topics: Adult; Atazanavir Sulfate; Carrier Proteins; Female; Gene Expression; HIV Protease Inhibitors; Humans; Inflammation; Interleukin-6; Intra-Abdominal Fat; Lopinavir; Male; Nelfinavir; Oligopeptides; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Pyridines; Pyrimidinones; Ritonavir; Sesquiterpenes; Subcutaneous Fat; Triglycerides; Tumor Necrosis Factor-alpha | 2011 |
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Body Fat Distribution; Body Mass Index; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Young Adult | 2011 |
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cost-Benefit Analysis; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Sweden | 2011 |
GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Biological Transport; Cells, Cultured; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Homeostasis; Humans; Insulin; Lopinavir; Male; Mice; Molecular Structure; Oligopeptides; Pyridines; Pyrimidinones; Rats; Rats, Wistar; Ritonavir | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atazanavir Sulfate; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Lopinavir; Macrophages; Mice; Mice, SCID; Mice, Transgenic; Nelfinavir; Neurons; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2012 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2011 |
Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Cell Differentiation; Cells, Cultured; Darunavir; HIV Protease Inhibitors; Humans; Insulin Resistance; Lipolysis; Lopinavir; Mice; Mitochondria; Oligopeptides; Pyridines; Reactive Oxygen Species; Ritonavir; Sulfonamides | 2012 |
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Topics: Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Virus Cultivation | 2012 |
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Costs and Cost Analysis; Drug Therapy, Combination; Health Status; HIV Protease Inhibitors; Humans; Lopinavir; Markov Chains; Oligopeptides; Pyridines; Quality of Life; Ritonavir; United Kingdom; Viral Load | 2012 |
Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.
Topics: AIDS Vaccines; Atazanavir Sulfate; Cell Line; HIV Antigens; HIV Protease Inhibitors; Humans; Lopinavir; Microbial Sensitivity Tests; Oligopeptides; Pyridines; Ritonavir; Vaccinia virus; Virus Replication | 2012 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors | 2013 |
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; HIV Infections; Humans; Italy; Lopinavir; Oligopeptides; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Ritonavir | 2013 |
HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin.
Topics: Adipogenesis; Antioxidants; Atazanavir Sulfate; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cellular Senescence; HIV Protease Inhibitors; Humans; Lopinavir; Mesenchymal Stem Cells; Oligopeptides; Osteoblasts; Oxidative Stress; Pravastatin; Pyridines | 2013 |
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2013 |
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.
Topics: Atazanavir Sulfate; CD4-Positive T-Lymphocytes; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HEK293 Cells; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation, Missense; Oligopeptides; Pyridines; Sulfonamides; Virus Internalization | 2013 |
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Topics: Animals; Astrocytes; Atazanavir Sulfate; Blood-Brain Barrier; Carbamates; Cell Line; Darunavir; Drug Resistance, Multiple, Viral; Endothelial Cells; Fluorides; Haplorhini; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Lopinavir; Models, Biological; Molecular Docking Simulation; Oligopeptides; Pericytes; Pyridines; Rats; Saquinavir; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lipids; Liver Function Tests; Lopinavir; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridines; RNA, Viral; Viral Load | 2014 |
Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cellular Senescence; Darunavir; Drug Synergism; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Nitric Oxide; Oligopeptides; Oxidative Stress; Pravastatin; Pyridines; Ritonavir; Sulfonamides | 2014 |
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; C-Reactive Protein; CD4 Lymphocyte Count; Chemokine CXCL10; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Immune System; Inflammation; Interferon-gamma; Interleukin-6; Lipopolysaccharide Receptors; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cell Extracts; Chromatography, Liquid; Cyclopropanes; Darunavir; Humans; Leukocytes, Mononuclear; Lopinavir; Mass Spectrometry; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2014 |
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Bone Density; HIV Infections; HIV-1; Humans; Lopinavir; Multivariate Analysis; Oligopeptides; Pyridines; Ritonavir | 2015 |
Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.
Topics: Adolescent; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Child; Cholesterol; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Retrospective Studies; Sulfonamides | 2014 |
Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Lopinavir; Nevirapine; Oligopeptides; Plasma; Pyridines; Retrospective Studies | 2014 |
Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: the role of NF-κB and PPAR-γ.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cytokines; Female; Hydrogen Peroxide; Immunity, Innate; Leishmania; Leishmaniasis; Lopinavir; Macrophages, Peritoneal; Mice, Inbred BALB C; NF-kappa B; Nitrites; PPAR gamma; Ritonavir | 2015 |
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Cooperative Behavior; Developed Countries; Europe; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States; Viral Load; Young Adult | 2015 |
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-Retroviral Agents; Asia; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Survival Analysis; Treatment Failure; Viral Load; Young Adult | 2015 |
Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Hospitals, Teaching; Humans; Lopinavir; Male; Middle Aged; Nigeria; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Lopinavir; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Topics: Adolescent; Adult; Atazanavir Sulfate; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Lopinavir; Middle Aged; Pregnancy; Pregnancy Outcome; Premature Birth; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2016 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Topics: Amphetamine-Related Disorders; Atazanavir Sulfate; Catalytic Domain; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Inactivation, Metabolic; Lopinavir; Methamphetamine; Microsomes, Liver; Molecular Docking Simulation; Nelfinavir; Protein Binding; Pyridines; Pyrones; Sulfonamides | 2016 |
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2016 |
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction.
Topics: Acetylcysteine; Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Ritonavir; Rotenone | 2016 |
Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations.
Topics: Atazanavir Sulfate; Biological Transport; Caco-2 Cells; Cell Membrane; Dosage Forms; Drug Compounding; Drug Liberation; HIV Protease Inhibitors; Humans; Lopinavir; Ritonavir; Solubility | 2016 |
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lopinavir; Male; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Retrospective Studies; Ritonavir | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Topics: Atazanavir Sulfate; Darunavir; DNA Replication; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Virus Replication; Zambia | 2016 |
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Uganda; Young Adult | 2016 |
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Treatment Outcome; United Kingdom | 2017 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Alkynes; Americas; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Darunavir; Europe; Female; HIV Protease Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Lopinavir; Male; Meningitis, Cryptococcal; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Toxoplasmosis | 2018 |
HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis.
Topics: Animals; Atazanavir Sulfate; Cytokines; Female; HIV Protease Inhibitors; Leishmaniasis; Leukocyte Count; Leukocytes; Lopinavir; Mice, Inbred BALB C; Nitric Oxide; Ritonavir; Skin; Spleen | 2018 |
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Endothelial Cells; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Lymphocyte Activation; Male; Prospective Studies; Pulse Wave Analysis; Random Allocation; Ritonavir | 2018 |
A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Multivariate Analysis; Mutation | 2019 |
Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes.
Topics: Acetyltransferases; Anti-HIV Agents; Astrocytes; Atazanavir Sulfate; Chromosomal Proteins, Non-Histone; Dideoxynucleosides; Drug Combinations; Emtricitabine; Gene Expression Regulation; Histone Deacetylases; HIV-1; Host-Pathogen Interactions; Humans; Lopinavir; Lysosomes; Membrane Proteins; Mitochondria; Morphine; Narcotics; Nuclear Proteins; Primary Cell Culture; Protein-Arginine N-Methyltransferases; Raltegravir Potassium; Ritonavir; Sequestosome-1 Protein; Signal Transduction; Trans-Activators; Virus Replication | 2019 |
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Ritonavir; Uganda; Viral Load | 2019 |
A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Namibia; Pharmacovigilance; Young Adult | 2019 |
HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes.
Topics: Animals; Aspartic Acid Endopeptidases; Atazanavir Sulfate; Babesia microti; Babesiosis; Erythrocytes; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Parasitemia; Protozoan Proteins | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Caco-2 Cells; Carbamates; Drug Interactions; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Imidazoles; Intestines; Lopinavir; Male; Maraviroc; Middle Aged; Pyrrolidines; Rats; Rats, Wistar; Ritonavir; Saquinavir; Valine; Zidovudine | 2019 |
COVID-19 & antiepileptic drugs: Should we pay attention?
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Carbamazepine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Lopinavir; Pandemics; Phenytoin; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Seizures | 2020 |
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Topics: Animals; Antiviral Agents; Atazanavir Sulfate; Betacoronavirus; Cell Death; Chlorocebus aethiops; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Cytokines; Drug Therapy, Combination; Humans; Inflammation; Lopinavir; Molecular Docking Simulation; Monocytes; Pandemics; Pneumonia, Viral; Protease Inhibitors; Ritonavir; SARS-CoV-2; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2020 |
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Emtricitabine; Humans; Lamivudine; Lopinavir; Molecular Docking Simulation; Nucleosides; Protease Inhibitors; Ritonavir; SARS-CoV-2 | 2021 |
Decoding molecular mechanism underlying binding of drugs to HIV-1 protease with molecular dynamics simulations and MM-GBSA calculations.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Binding Sites; HIV Protease; Lopinavir; Molecular Dynamics Simulation; Nelfinavir | 2021 |
Potential interactions between antineoplastic agents and medicines used to treat Covid-19.
Topics: Antineoplastic Agents; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Humans; Lopinavir; Ritonavir | 2022 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Length of Stay; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
Evaluation of COVID-19 protease and HIV inhibitors interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; Darunavir; Humans; Lopinavir; Molecular Docking Simulation; Peptide Hydrolases; Protease Inhibitors | 2022 |
Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily G, Member 2; Darunavir; Drug Interactions; Lopinavir; Neoplasm Proteins; Protease Inhibitors; Ritonavir; Rosuvastatin Calcium | 2023 |